M. Neil Reaume

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis, Andrew Martin, Martin R. Stockler et al. · New England Journal of Medicine · 2019 · 1.5K citations

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

Robert J. Motzer, Naomi B. Haas, Frede Donskov et al. · Journal of Clinical Oncology · 2017 · 382 citations

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

Karim Fizazi, Josep M. Piulats, M. Neil Reaume et al. · New England Journal of Medicine · 2023 · 380 citations · Full text

Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival

Shaan Dudani, Guillermo de Velasco, J. Connor Wells et al. · JAMA Network Open · 2021 · 273 citations · Full text

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

Christopher J. Sweeney, Andrew Martin, Martin R. Stockler et al. · The Lancet Oncology · 2023 · 175 citations

Urology, Oncology, Genitourinary Cancer +7